Investing Profile

Dominic Schmidt

InvestorVC
General Partner at Advent Life Sciences
Photo of Dominic Schmidt, General Partner at Advent Life Sciences

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
Hotmail Network
4899 CONNECTIONS
Hotmail Network
4899 CONNECTIONS
University of Cambridge Network
258 CONNECTIONS
L.E.K. Consulting Network
49 CONNECTIONS
Freie Universität Berlin Network
13 CONNECTIONS
cb
Advent Life Sciences General Partner
$25K - $5.0M
$1M
2
CompanyStageDateRound SizeTotal Raised
Glycomine
Series CApr 2025$120M
$150M
Co-investors: Jim Trenkle (Sanofi Ventures), Bali Muralidhar (Abingworth), Niall O’Donnell (RiverVest)
Purespring Therapeutics
Series ANov 2020$60M
$170M
Co-investors: Maina Bhaman (Sofinnova Partners)
Master Student and Research Assistant Max Planck Institute for Molecular Genetics (MPI-MG)Present
Doctoral Student Cancer Research UK (CRUK)Present
Associate L.E.K. ConsultingPresent
Board Observer Spur TherapeuticsPresent
Non Executive Director HotmailPresent
Non Executive Director and Board Observer HotmailPresent
Non Executive Director Purespring TherapeuticsPresent
Non Executive Director Amphista Therapeutics LimitedPresent
Non Executive Director AviadoBioPresent
Non Executive Director Pheno Therapeutics LtdPresent
Board Observer Beacon TherapeuticsPresent
Non Executive Director Glycomine Inc.Present
Partner Syncona LimitedPresent
General Partner Advent Life SciencesPresent
Freie Universität Berlin German Diplom Degree / M.Sc. Biochemistry
University of Cambridge Doctor of Philosophy (Ph.D.) Oncology